Swiss Re AG · SIX:SREN
Swiss Re — Investor Presentation (February 2021)
11 slides from Swiss Re's investor presentation, February 2021
Slide 1: Advances in Therapeutics
Advances in Therapeutics Nicola Charlton MD MPH DBIM, February 2021, R&D 1
Slide 2: World Health Organization
World Health Organization There is only one way the world can exit this pandemic-and that is through science. We need Diagnostics to detect and limit the spread of this virus, vaccines to provide long-term protection, treatments to save lives in the short- term and social sciences to understand the
Slide 3: Wicked Problems
Wicked Problems 01 Difficult to solve, no clear solution, not a right or wrong answer but a better or worse 02 Socially complex, difficult to define. 03 Stands astride organizational boundaries and responsibilities 04 Multiple stakeholder ,multi casual 05 Involves behaviour change, Nicola Charlton M
Slide 4: Theoretical Model of Disease Progression and Targeted Therapies Based on Current Literature
Theoretical Model of Disease Progression and Targeted Therapies Based on Current Literature RECOVERY TRIAL-28-day mortality Salim Rezaie, Author at REBEL EM - Emergency Medicine Blog Nicola Charlton MD MPH DBIM | February 2021 | R&D 4
Slide 5: Several vaccines have been approved, and widespread rollout has begun
Several vaccines have been approved, and widespread rollout has begun Company Type Doses Efficacy Storage Approvals Moderna mRNA 2 94% -20°C a.o. Pfizer – BioNTech mRNA 2 95% -70°C a.o. AstraZeneca – Oxford Modified viral vector 2 62 – 90% 4°C a.o. Gamalaya (Sputnik V) Modified viral vector 2 92% 4°
Slide 6: Major market dosage availability and total doses
Major market dosage availability and total doses EU Moderna Japan Canada Pfizer/BioNTech US UK AstraZeneca 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 Doses per capita 0 200 400 600 800 1000 1200 Total doses (millions) AstraZeneca Pfizer/BioNTech Moderna UK US Canada Japan EU Source: Launch & Scale Faster – upd
Slide 7: Vaccine progress lowers hospitalisation & mortality
Vaccine progress lowers hospitalisation & mortality 70 60 50 40 30 20 10 0 Israel United Kingdom United States Germany Canada World European Union Source: Our World in Data 9th Feb 2021, NicolaFT.com Charlton MD MPH DBIM | February 2021 | R&D 7
Slide 8: Vaccine acceptance rates may become an issue
Vaccine acceptance rates may become an issue If and when a COVID-19 vaccine becomes available, will you get vaccinated? UK 80 11 9 India 67 16 17 Spain 66 20 14 Australia 64 21 15 Italy 64 15 21 China 61 24 15 Sweden 55 24 21 Germany 51 22 27 USA 47 26 27 France 39 23 38 Yes Don't know No Source: Yo
Slide 9: Thank you!
Thank you! Contact us Follow us Nicky Charlton, MD, MPH, DBIM UW R&D Senior Medical Officer, Globals L&H [email protected] +1-856-446-9758 9
Slide 10: Legal notice
Legal notice ©2021 Swiss Re. All rights reserved. You may use this presentation for private or internal purposes but note that any copyright or other proprietary notices must not be removed. You are not permitted to create any modifications or derivative works of this presentation, or to use it for
Slide 11: Nicola Charlton MD MPH DBIM | February 2021 | R&D
Nicola Charlton MD MPH DBIM | February 2021 | R&D 11